Data from the MagSense® HER2 Phase 1 study and internal R&D programs have opened new opportunities for Imagion to file for intellectual property and are driving efforts to investigate how analytical methods in Artificial Intelligence (AI) and Machine Learning (ML) might be applied to improve the clinical utility of the MagSense® imaging tests
You might want to look closer at the statements in your linked documents, there are lots of could/should/would etc doesn’t mean that money is going to be rolling in the door anytime soon.
